Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | SELE | P16581 | 1/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18517201 | 0.82 | DAO (0.37) | NPC1DAO | |
| SCHEMBL18874103 | 0.82 | DAO (0.37) | NPC1DAO | |
| SCHEMBL13621245 | 0.79 | DPP4 (0.41) | KMT2AMEN1NPC1RAB9ADPP4 | |
| SCHEMBL20814635 | 0.77 | DPP4 (0.44) | KMT2AMEN1NPC1RAB9ADPP4 | |
| SCHEMBL2027946 | 0.77 | DPP4 (0.44) | KMT2AMEN1NPC1RAB9ADPP4 | |
| SCHEMBL12031412 | 0.76 | ALDH1A1 (0.47) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10471752 | 0.75 | ALDH1A1 (0.46) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9773308 | 0.74 | DAO (0.44) | DAO | |
| SCHEMBL12362134 | 0.74 | PRMT6 (0.43) | KMT2AMEN1NPC1RAB9ADPP4 | |
| SCHEMBL14455869 | 0.72 | CYP2A6 (0.42) | KMT2AMEN1NPC1RAB9ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328102-B2 | Slow release of organoboronic acids in cross-coupling reactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150246905-A1 | Slow Release of Organoboronic Acids in Cross-Coupling Reactions | NATIONAL SCIENCE FOUNDATION | 2015-09-03 | — | — | US | disclosed |
| US-9006463-B2 | Slow release of organoboronic acids in cross-coupling reactions | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246905-A1 | Slow Release of Organoboronic Acids in Cross-Coupling Reactions | BRS3, CD79B, GRB2 | KMT2A 3510/4885MEN1 1153/4885NPC1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.